Related Experiment Video

Updated: May 5, 2026

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.2K

Complete revascularization versus culprit-lesion only PCI in patients with NSTEMI and multivessel disease - Design

Hans-Josef Feistritzer1, Alexander Jobs1, Uwe Zeymer2

  • 1Department of Internal Medicine/Cardiology, Heart Center Leipzig at Leipzig University and Leipzig Heart Science, Leipzig, Germany.

American Heart Journal
|April 10, 2025
PubMed

Insights

The COMPLETE-NSTEMI trial compares complete versus culprit-lesion only percutaneous coronary intervention (PCI) in non-ST-segment elevation myocardial infarction (NSTEMI) patients with multivessel coronary artery disease (CAD). This study will determine the optimal revascularization strategy for improved patient outcomes.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Clinical Trials

Background:

  • Multivessel coronary artery disease (CAD) affects 30-70% of non-ST-segment elevation myocardial infarction (NSTEMI) patients.
  • Limited randomized controlled trial (RCT) evidence exists for complete revascularization strategies in NSTEMI patients with multivessel CAD.

Purpose of the Study:

  • To investigate if multivessel percutaneous coronary intervention (PCI) is superior to culprit-lesion only PCI in NSTEMI patients with multivessel CAD.
  • To establish the optimal revascularization strategy for this patient population.

Main Methods:

  • Prospective, randomized, controlled, multicenter, open-label trial (COMPLETE-NSTEMI).
  • Enrollment of 3390 NSTEMI patients with multivessel CAD.
  • Randomization of patients 1:1 to either complete PCI or culprit-lesion only PCI.

Main Results:

  • The primary efficacy endpoint is a composite of cardiovascular death or rehospitalization for nonfatal myocardial infarction.
  • The trial is event-driven, aiming for 578 primary endpoint events with a minimum 12-month follow-up.
  • Recruitment completion is expected in the first half of 2027, with final results anticipated in 2028.

Conclusions:

  • The COMPLETE-NSTEMI trial is the first dedicated study to address the optimal revascularization strategy in NSTEMI patients with multivessel CAD.
  • Findings will provide crucial evidence to guide clinical decision-making for this patient group.
Abstract

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.5K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
943
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493